ArticleThe Laryngoscope2016
Classification of TP53 mutations and HPV predict survival in advanced larynx cancer.
Article in The Laryngoscope, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026Review
- Global, regional, and national mortality of larynx cancer from 1990 to 2021: results from the global burden of disease study.World journal of surgical oncology · 2025Article
- Laryngeal sarcomatoid carcinoma: a case report and literature review on potential molecular targets for therapeutic opportunities.Frontiers in oncology · 2025Article
- Article
- Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives.Cancers · 2021Review
- Investigation of the affective factors on the survival rate of patients with laryngeal cancer using Cox proportional hazards and Lin -Ying's additive hazards models.Medical journal of the Islamic Republic of Iran · 2021Article
- Blocking of EGFR Signaling Is a Latent Strategy for the Improvement of Prognosis of HPV-Induced Cancer.Frontiers in oncology · 2021Article
- Characteristics of head and neck squamous cell carcinoma cell Lines reflect human tumor biology independent of primary etiologies and HPV status.Translational oncology · 2020Article
- HPV in non-oropharyngeal head and neck cancer: does it matter?Annals of translational medicine · 2020Article
- Transcriptome Analysis Identifies ALCAM Overexpression as a Prognosis Biomarker in Laryngeal Squamous Cell Carcinoma.Cancers · 2020Article
- In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer.Medical oncology (Northwood, London, England) · 2019Article
- Effect of HPV Infection on the Occurrence and Development of Laryngeal Cancer: A Review.Journal of Cancer · 2019Review
- Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients.International journal of biological sciences · 2019Article
- [HPV - A different view on Head and Neck Cancer].Laryngo- rhino- otologie · 2018Review
- The role of high-risk human papillomavirus infections in laryngeal squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2017Review
- Tumor risk markers in recurrent respiratory papillomatosis.Brazilian journal of otorhinolaryngologyArticle
- Clinical, Histological and Immunohistochemical Evaluation of Larynx Cancer.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectives/hypothesisAssess tumor suppressor p53 (TP53) functional mutations in the context of other biomarkers in advanced larynx cancer. STUDY
designProspective analysis of pretreatment tumor TP53, human papillomavirus (HPV), Bcl-xL, and cyclin D1 status in stage III and IV larynx cancer patients in a clinical trial.
methodsTP53 exons 4 through 9 from 58 tumors were sequenced. Mutations were grouped using three classifications based on their expected function. Each functional group was analyzed for response to induction chemotherapy, time to surgery, survival, HPV status, p16INK4a, Bcl-xl, and cyclin D1 expression.
resultsTP53 mutations were found in 22 of 58 (37.9%) patients with advanced larynx cancer, including missense mutations in 13 of 58 (22.4%) patients, nonsense mutations in four of 58 (6.9%), and deletions in five of 58 (8.6%). High-risk HPV was found in 20 of 52 (38.5%) tumors. A classification based on Evolutionary Action score of p53 (EAp53) distinguished missense mutations with high risk for decreased survival from low-risk mutations (P = 0.0315). A model including this TP53 classification, HPV status, cyclin D1, and Bcl-xL staining significantly predicts survival (P = 0.0017).
conclusionEAp53 functional classification of TP53 mutants and biomarkers predict survival in advanced larynx cancer. LEVEL OF EVIDENCE: NA. Laryngoscope, 126:E292-E299, 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.